ATE373827T1 - Kombination von markern für diabetes typ 1 und 2 - Google Patents
Kombination von markern für diabetes typ 1 und 2Info
- Publication number
- ATE373827T1 ATE373827T1 AT05014522T AT05014522T ATE373827T1 AT E373827 T1 ATE373827 T1 AT E373827T1 AT 05014522 T AT05014522 T AT 05014522T AT 05014522 T AT05014522 T AT 05014522T AT E373827 T1 ATE373827 T1 AT E373827T1
- Authority
- AT
- Austria
- Prior art keywords
- markers
- risk
- cardiovascular complication
- suffering
- diabetes
- Prior art date
Links
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 3
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 6
- 238000000034 method Methods 0.000 abstract 3
- 230000000747 cardiac effect Effects 0.000 abstract 2
- 239000005556 hormone Substances 0.000 abstract 2
- 229940088597 hormone Drugs 0.000 abstract 2
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 abstract 1
- 102400000667 Brain natriuretic peptide 32 Human genes 0.000 abstract 1
- 101800002247 Brain natriuretic peptide 45 Proteins 0.000 abstract 1
- 102400000432 CD40 ligand, soluble form Human genes 0.000 abstract 1
- 101800000267 CD40 ligand, soluble form Proteins 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 102400001263 NT-proBNP Human genes 0.000 abstract 1
- 108020001621 Natriuretic Peptide Proteins 0.000 abstract 1
- 102000004571 Natriuretic peptide Human genes 0.000 abstract 1
- 108010082093 Placenta Growth Factor Proteins 0.000 abstract 1
- 102100035194 Placenta growth factor Human genes 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 238000005259 measurement Methods 0.000 abstract 1
- 239000000692 natriuretic peptide Substances 0.000 abstract 1
- 230000010118 platelet activation Effects 0.000 abstract 1
- 108010008064 pro-brain natriuretic peptide (1-76) Proteins 0.000 abstract 1
- 238000013517 stratification Methods 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4737—C-reactive protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/515—Angiogenesic factors; Angiogenin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
- G01N2333/5412—IL-6
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/12—Growth hormone, growth factor other than t-cell or b-cell growth factor, and growth hormone releasing factor; related peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/14—Lymphokine; related peptides
- Y10S930/141—Interleukin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Rehabilitation Therapy (AREA)
- Rheumatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04015935 | 2004-07-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE373827T1 true ATE373827T1 (de) | 2007-10-15 |
Family
ID=35541816
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05014522T ATE373827T1 (de) | 2004-07-07 | 2005-07-05 | Kombination von markern für diabetes typ 1 und 2 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US7960123B2 (de) |
| JP (1) | JP4272642B2 (de) |
| AT (1) | ATE373827T1 (de) |
| CA (1) | CA2511269A1 (de) |
| DE (1) | DE602005002500T2 (de) |
| ES (1) | ES2294598T3 (de) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
| DE50309809D1 (de) | 2002-11-16 | 2008-06-19 | Dade Behring Marburg Gmbh | Scd40l, papp-a und plazentaler-wachstumsfaktor (pigf) als biochemische markerkombinationen bei kardiovaskulären erkrankungen |
| DE102004051847B4 (de) * | 2004-10-25 | 2008-09-18 | Dade Behring Marburg Gmbh | Verhältnis von PIGF und Flt-1 als prognostischer Parameter bei kardio-vaskulären Erkrankungen |
| EP1837659B1 (de) * | 2006-03-24 | 2010-06-09 | F. Hoffman-la Roche AG | Vorrichtung und Verfahren zur Unterscheidung zwischen akuter und chronischer Myokardial-Nekrose bei symptomatischen Patienten |
| EP1852108A1 (de) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | Zusammensetzungen von DPP-IV-Inhibitoren |
| PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
| CN102838599A (zh) | 2006-05-04 | 2012-12-26 | 贝林格尔.英格海姆国际有限公司 | 多晶型 |
| EP2602624A1 (de) * | 2006-08-07 | 2013-06-12 | Antibodyshop A/S | Diagnostischer Test zum Ausschliessen einer signifikanten Nierenverletzung |
| DE602006015964D1 (de) * | 2006-09-20 | 2010-09-16 | Roche Diagnostics Gmbh | Natriurethische Peptide und Plazenta-Wachstumfaktor/löslicher VEGF-Rezeptor unterscheiden zwischen mit der Plazenta verbundener Herzdysfunktion und mit Herzerkrankung verbundener Herzdysfunktion |
| ES2430290T3 (es) * | 2007-03-06 | 2013-11-19 | F. Hoffmann-La Roche Ag | Utilización de péptidos de tipo PNC para predecir la necesidad de diálisis |
| WO2009004443A2 (en) * | 2007-07-04 | 2009-01-08 | Medizinische Universität Wien | Compositions for the detection of gene expression in diabetic microangiopathy |
| PE20091730A1 (es) | 2008-04-03 | 2009-12-10 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
| EP2120051B1 (de) * | 2008-05-13 | 2011-08-31 | Roche Diagnostics GmbH | Mittel und Verfahren zur Prognose von Nierenversagen bei Diabetikern auf Basis des plazentalen Wachstumsfaktors und löslichem Flt-1 |
| JP2011523051A (ja) * | 2008-05-20 | 2011-08-04 | エフ．ホフマン−ラ ロシュ アーゲー | １型糖尿病におけるバイオマーカーとしてのｇｄｆ−１５ |
| US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
| EP2496946B1 (de) | 2009-11-03 | 2015-07-15 | Roche Diagniostics GmbH | NT-pro-ANP und sFlt-1 zur Differenzierung zwischen Kreislauf- und Ischämiereignissen |
| EA201290311A1 (ru) * | 2009-11-13 | 2012-12-28 | БиДжи МЕДИСИН, ИНК. | Факторы риска и прогнозирование инфаркта миокарда |
| US8602996B2 (en) | 2010-06-01 | 2013-12-10 | Cardiac Pacemakers, Inc. | Integrating device-based sensors and bedside biomarker assays to detect worsening heart failure |
| AR083878A1 (es) | 2010-11-15 | 2013-03-27 | Boehringer Ingelheim Int | Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento |
| US20130196870A1 (en) * | 2012-01-31 | 2013-08-01 | Medical University Of South Carolina | Systems and methods using biomarker panel data |
| US10502747B2 (en) | 2012-01-31 | 2019-12-10 | Cardiac Pacemakers, Inc. | Systems and methods using biomarker panel data |
| EP3685839A1 (de) | 2012-05-14 | 2020-07-29 | Boehringer Ingelheim International GmbH | Linagliptin zur verwendung in der behandlung von albuminuria und nierenbedingten erkrankungen |
| US20130303554A1 (en) | 2012-05-14 | 2013-11-14 | Boehringer Ingelheim International Gmbh | Use of a dpp-4 inhibitor in sirs and/or sepsis |
| CA2818328C (en) * | 2012-06-11 | 2017-09-05 | Preventage Healthcare Llc | Methods for improving diabetes management |
| WO2017211979A1 (en) | 2016-06-10 | 2017-12-14 | Boehringer Ingelheim International Gmbh | Combinations of linagliptin and metformin |
| US12322100B2 (en) | 2018-12-11 | 2025-06-03 | Eko.Ai Pte. Ltd. | Automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images for automated cardiac measurements and grading of aortic stenosis severity |
| US12400762B2 (en) | 2018-12-11 | 2025-08-26 | Eko.Ai Pte. Ltd. | Automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images for automated cardiac measurements and diagnosis of cardiac amyloidosis and hypertrophic cardiomyopathy |
| US11446009B2 (en) | 2018-12-11 | 2022-09-20 | Eko.Ai Pte. Ltd. | Clinical workflow to diagnose heart disease based on cardiac biomarker measurements and AI recognition of 2D and doppler modality echocardiogram images |
| US12001939B2 (en) | 2018-12-11 | 2024-06-04 | Eko.Ai Pte. Ltd. | Artificial intelligence (AI)-based guidance for an ultrasound device to improve capture of echo image views |
| US11931207B2 (en) | 2018-12-11 | 2024-03-19 | Eko.Ai Pte. Ltd. | Artificial intelligence (AI) recognition of echocardiogram images to enhance a mobile ultrasound device |
| CA3155843A1 (en) * | 2019-09-27 | 2021-04-01 | Arterez, Inc. | Biomarker panel targeted to diseases due to multifactorial ontology of glycocalyx disruption |
| CN110794135A (zh) * | 2019-10-31 | 2020-02-14 | 安徽大千生物工程有限公司 | Gpbb胶乳增强比浊法检测试剂盒及其制备使用方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5744101A (en) | 1989-06-07 | 1998-04-28 | Affymax Technologies N.V. | Photolabile nucleoside protecting groups |
| JPH08245424A (ja) * | 1995-03-06 | 1996-09-24 | Toagosei Co Ltd | 糖尿病性腎症診断剤 |
| ATE315789T1 (de) * | 1999-11-16 | 2006-02-15 | Genentech Inc | Elisa für vegf |
| DE50309809D1 (de) * | 2002-11-16 | 2008-06-19 | Dade Behring Marburg Gmbh | Scd40l, papp-a und plazentaler-wachstumsfaktor (pigf) als biochemische markerkombinationen bei kardiovaskulären erkrankungen |
| JP4610025B2 (ja) * | 2002-11-18 | 2011-01-12 | シン．クス ファーマ、インコーポレイテッド | ＮＴ−ｐｒｏＢＮＰ検出用ポリクローナル・モノクローナル・エライサ検定法 |
-
2005
- 2005-06-30 CA CA002511269A patent/CA2511269A1/en not_active Abandoned
- 2005-07-05 AT AT05014522T patent/ATE373827T1/de active
- 2005-07-05 DE DE602005002500T patent/DE602005002500T2/de not_active Expired - Lifetime
- 2005-07-05 ES ES05014522T patent/ES2294598T3/es not_active Expired - Lifetime
- 2005-07-06 US US11/175,933 patent/US7960123B2/en not_active Expired - Fee Related
- 2005-07-06 JP JP2005197634A patent/JP4272642B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2511269A1 (en) | 2006-01-07 |
| ES2294598T3 (es) | 2008-04-01 |
| JP4272642B2 (ja) | 2009-06-03 |
| DE602005002500D1 (de) | 2007-10-31 |
| US20060008829A1 (en) | 2006-01-12 |
| DE602005002500T2 (de) | 2008-06-12 |
| US7960123B2 (en) | 2011-06-14 |
| JP2006030183A (ja) | 2006-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602005002500D1 (de) | Kombination von Markern für Diabetes Typ 1 und 2 | |
| ATE364177T1 (de) | Kombinationen von markern zum nachweis von typ 1 und 2 diabetes | |
| ATE469353T1 (de) | Verwendung von nt-proanp und nt-probnp zur diagnose von herzerkrankungen | |
| ATE403157T1 (de) | Verwendung des bnp-art und anp-art peptiden für das festsetzen der gefahren von herzgefäss- komplikationen als folge der volumenüberlastung | |
| Gessler et al. | Prognostic value of plasma N-terminal pro-brain natriuretic peptide in children with congenital heart defects and open-heart surgery | |
| JP5275247B2 (ja) | ＭＲ−ｐｒｏＡＤＭを用いる糖尿病の検出および糖尿病の合併症の有無の検出 | |
| Douillard et al. | SFE/SFHTA/AFCE Consensus on Primary Aldosteronism, part 2: First diagnostic steps | |
| JP2010513879A5 (de) | ||
| Kim et al. | Effects of marathon running on cardiac markers and endothelin-1 in EIH athletes | |
| RU2015108959A (ru) | Способы прогнозирования риска развития гипертензии | |
| JP2008046129A5 (de) | ||
| DK1644740T3 (da) | Vurdering af skeletal vækst ved anvendelse af målinger af NT-CNP-peptider | |
| MX339184B (es) | Panel multimarcador para hipertrofia ventricular izquierda. | |
| WO2009087190A1 (en) | Means and methods for assessing the risk of patients presenting to emergency units based on gdf-15 | |
| JP2006502203A5 (de) | ||
| ATE412910T1 (de) | Verwendung von herzhormonen zur diagnose des kardiovaskuläre risikos als folge einer verabreichung von entzündungshemmern | |
| ES2549460T3 (es) | NT-pro ANP y sFlt-1 para la diferenciación entre los eventos isquémicos y circulatorios | |
| CA2567738A1 (en) | The use of cardiac hormones for diagnosing the risk of suffering from a cardiovascular complication as a consequence of cardiotoxic medication | |
| Okura et al. | Undercarboxylated osteocalcin is a biomarker of carotid calcification in patients with essential hypertension | |
| US9482678B1 (en) | Method for measurement of bioavailable testosterone | |
| JP2012516436A5 (de) | ||
| ATE476665T1 (de) | Natriurethische peptide und plazenta- wachstumfaktor/löslicher vegf-rezeptor unterscheiden zwischen mit der plazenta verbundener herzdysfunktion und mit herzerkrankung verbundener herzdysfunktion | |
| ES2657087T3 (es) | Monitorización de péptidos natriuréticos cardiacos durante el diagnóstico, manejo y tratamiento de enfermedades cardiacas | |
| İyidir et al. | Evaluation of ambulatory arterial stiffness index in hyperthyroidism | |
| Abrahams et al. | Use of the WHO hemoglobin color scale in family welfare clinics in India |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1615036 Country of ref document: EP |